The UK and US have agreed to a landmark bilateral deal that will ensure zero duties on British pharmaceutical shipments being sold in the US market.
Key Provisions of the Accord
As part of the deal, the UK has committed to increase expenditure on medicines through the National Health Service (NHS). This commitment guarantees that tariffs on these vital exports will stay at zero for a timeframe of the next three years.
This agreement comes after recent threats to hike import taxes on branded pharmaceutical imports, with increases floated as high as 100%.
"This arrangement with the UK strengthens the worldwide climate for cutting-edge drugs and introduces long-overdue equity to U.S.–U.K. pharmaceutical trade," a release said.
Commercial Significance
Drugs are one of the Britain's largest goods shipped to the America, which is by far the biggest market for major British pharmaceutical firms.
Statistics reveal that in the year leading up to the third quarter, the UK shipped medicines worth billions to the US. This amount represented nearly one-fifth of all goods exports in that timeframe.
"This agreement secures work, boosts investment and paves the way for the UK to emerge as a worldwide center for biotech and pharma," a minister commented.
Detailed UK Commitments
The deal involves several notable pledges from the British government:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it deems new therapies to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a aim to double total public funding on treatments from 0.3% of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The percentage manufacturers must return to the NHS to control costs will be capped at fifteen percent. Last year, rebates were more than 20%.
Industry Background
This agreement follows a long-running dispute between the drug companies and the ministers over spending levels and NHS adoption.
The disagreement were intensified by arguments that US customers were paying significantly more for the same drugs than patients in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been halted or abandoned, while multi-billion-dollar expansions have been directed toward projects in the United States.
A senior figure stated that the NHS needed to invest a greater share on medicines, noting that its budget allocation on drugs had shrunk as a proportion of its total funding over the previous ten-year period.